Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniel Vinh

Otolaryngology Indianapolis, IN Medical Doctor

NPI 1801241534 CMS profile 9428892

550 University Blvd, Indianapolis, IN 46202

Open in the dashboard

General payments

$8,922

53 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$38,488 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Daniel Vinh of Indianapolis, IN is reported in the CMS Open Payments database as having received $8,922 across 53 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $38,488 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,629 16
2024 General $4,869 22
2023 General $2,069 11
2022 General $177 2
2021 General $178 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Vinh
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Daniel Vinh were reported at $1,629. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Daniel Vinh Otolaryngology median Middle half National median
2019 $0 $194 $82–$512 $163
2020 $0 $118 $42–$280 $114
2021 $178 $167 $63–$444 $132
2022 $177 $216 $84–$545 $149
2023 $2,069 $235 $93–$588 $160
2024 $4,869 $280 $111–$699 $164
2025 $1,629 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Intuitive Surgical, Inc. $3,663 9 payments
  2. AxoGen $2,287 11 payments
  3. KLS-Martin L.P. $682 5 payments
  4. DePuy Synthes Sales Inc. $333 4 payments
  5. Acera Surgical, Inc. $268 2 payments
  6. Integra LifeSciences Corporation $253 3 payments
  7. Zimmer Biomet Holdings, Inc. $161 2 payments
  8. Inspire Medical Systems, Inc. $160 1 payment
  9. Access Pro Medical, LLC $144 1 payment
  10. Checkpoint Surgical, Inc $129 1 payment
  11. Other $840 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,317 44 payments
  2. Education $2,500 1 payment
  3. Travel and Lodging $2,104 8 payments
Products named General payments · program years 2021–2025
  1. DA VINCI SP $2,500 1 payment
  2. Avance Nerve Graft $1,986 8 payments
  3. AxoGuard Nerve Connector $1,842 6 payments
  4. AXOGUARD NERVE PROTECTOR $1,842 6 payments
  5. Da Vinci Surgical System $1,163 8 payments
  6. TRUMATCH $316 3 payments
  7. Restrata Wound Matrix $268 2 payments
  8. MATRIXMANDIBLE $260 3 payments
  9. TraumaOne $161 2 payments
  10. Inspire Upper Airway Stimulation System $160 1 payment
  11. Other $2,931 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

72

Median for Otolaryngology: 297

Drug cost

$483

Median for Otolaryngology: $6,314

Branded share of claims

66.7%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 18 $188
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 30 $179
Omeprazole Generic 11 $74
Chlorhexidine Gluconate Generic 13 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$54,530

Medicare's payments for the services billed

Medicare patients

143

Average age 72

Services billed

329

59 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Ischemic heart disease 31%
Depression 29%
COPD 25%
Chronic kidney disease 24%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record